Clinical Trial: Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: International Prospective Phase 2 Trial Addressing the Efficacy of First-line Chlamydophila Psittaci-eradicating Therapy With Protracted Administration of Doxycycline Followed by Eradication Monitorin

Brief Summary: Objective of this trial is to establish the efficacy of an upfront targeted therapy consisting of Chlamydophila psittaci (Cp)-eradicating therapy with prolonged administration of doxycycline followed by eradication monitoring and antibiotic re-treatment at infection re-occurrence in patients with newly diagnosed ocular adnexae marginal zone lymphoma The primary endpoint is the 2-year progression-free survival (PFS) of patients with newly diagnosed stage-IE lymphoma treated with the experimental strategy.

Detailed Summary:
Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Current Primary Outcome: progression-free survival (PFS) [ Time Frame: 2-year from start of treatment ]

from the date of the start of treatment to relapse, progression or death, or to the last date of follow-up


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: International Extranodal Lymphoma Study Group (IELSG)

Dates:
Date Received: March 26, 2013
Date Started: March 2013
Date Completion: September 2023
Last Updated: July 26, 2016
Last Verified: July 2016